<p>Protara Therapeutics, Inc.（纳斯达克代码：TARA - 免费报告）- HC Wainwright 在 11 月 24 日星期一发布的报告中上调了 Protara Therapeutics 2025 年第四季度每股收益（EPS）预期。HC Wainwright 分析师 A. Maldonado 现在预计该公司本季度每股收益为（$0.32），高于之前预测的（$0.36）。HC Wainwright 对该股票给予 “买入” 评级，目标价为$23.00。Protara Therapeutics 当前全年的共识收益预期为每股（$3.32）。HC Wainwright 还发布了 Protara Therapeutics 2026 年第一季度每股收益预期为（$0.33），2026 财年每股收益预期为（$1.37），2027 财年每股收益预期为（$1.70），2028 财年每股收益预期为（$0.95）以及 2029 财年每股收益预期为（$0.34）。</p>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的报告中重新发布了 Protara Therapeutics 的 “卖出（d-）” 评级。一位分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，还有一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Protara Therapeutics 的平均评级为 “适度买入”，共识目标价为$19.60。</p>
<p>获取 <strong>Protara Therapeutics</strong> 警报：</p>
<p><strong>获取我们对 TARA 的最新分析</strong></p>
<h2>Protara Therapeutics 股价上涨 2.6%</h2>
<p>TARA 股票在星期三开盘价为$7.56。该公司的 50 日移动平均线为$5.07，200 日移动平均线为$3.82。该股票的市值为$2.9172 亿，市盈率为-4.67，贝塔值为 1.59。Protara Therapeutics 的 1 年最低价为$2.48，1 年最高价为$10.48。</p>
<p>Protara Therapeutics（纳斯达克代码：TARA - 获取免费报告）最近一次发布财报是在 11 月 10 日星期一。该公司报告本季度每股收益为（$0.31），超出共识预期的（$0.39）$0.08。</p>
<h2>Protara Therapeutics 的机构交易</h2>
<p>一些机构投资者最近对该股票的持仓进行了调整。洛杉矶资本管理公司在第二季度购买了 Protara Therapeutics 的新股份，价值$47,000。Velan Capital Investment Management LP 在第一季度增加了对 Protara Therapeutics 的持仓，增幅为 5.6%。Velan Capital Investment Management LP 现在拥有 1,667,800 股该公司的股票，价值$7,105,000，在此期间又收购了 88,800 股。Walleye Capital LLC 在第一季度将其在 Protara Therapeutics 的股份提高了 3.9%。Walleye Capital LLC 现在拥有 229,454 股该公司的股票，价值$977,000，在上个季度又收购了 8,640 股。查尔斯·施瓦布投资管理公司在第一季度购买了 Protara Therapeutics 的新股份，价值约$64,000。最后，美国世纪公司在第一季度购买了 Protara Therapeutics 的新股份，价值约$154,000。对冲基金和其他机构投资者持有该公司 38.13% 的股份。</p>
<h2>关于 Protara Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Protara Therapeutics, Inc.是一家临床阶段的生物制药公司，致力于推进用于治疗癌症和罕见疾病的变革性疗法。该公司的主导项目是 TARA-002，一种正在进行的细胞疗法，目前处于针对非肌肉侵袭性膀胱癌和淋巴畸形的二期临床试验中。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比 Protara Therapeutics 更好</li>
<li>什么是财报？</li>
<li>历史表明这三只股票适合在 12 月购买</li>
<li>高分红 REIT：它们是理想的多元化方式吗？</li>
<li>华纳兄弟出售传闻升温：投资者需要知道什么</li>
<li>三只小盘股具有巨大的回报潜力</li>
<li>从科学项目到溶剂：WeRide 的 761% 收入激增</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Protara Therapeutics 吗？</h2>
<p>在考虑 Protara Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Protara Therapeutics 并不在名单上。</p>
<p>虽然 Protara Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TARA

<p>HC Wainwright 已经上调了 Protara Therapeutics 2025 年第四季度每股收益（EPS）的预期，现在预计为每股（$0.32），之前为（$0.36）。该公司维持 “买入” 评级，目标价为 $23.00。Protara 的股票开盘价为 $7.56，市值为 $2.9172 亿。分析师对其给予 “适度买入” 评级，但 Weiss Ratings 则发布了 “卖出” 评级。机构投资者持有该股票的 38.13%。Protara 正在推进癌症和罕见疾病的治疗，主要项目 TARA-002 正在进行第二阶段临床试验</p>

<p>Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - HC Wainwright upped their Q4 2025 earnings per share (EPS) estimates for shares of Protara Therapeutics in a report released on Monday, November 24th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their previous forecast of ($0.36). HC Wainwright has a &#34;Buy&#34; rating and a $23.00 price objective on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics' Q1 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.70) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.34) EPS.</p>
<div class="lb-trans"><p>Protara Therapeutics, Inc.（纳斯达克代码：TARA - 免费报告）- HC Wainwright 在 11 月 24 日星期一发布的报告中上调了 Protara Therapeutics 2025 年第四季度每股收益（EPS）预期。HC Wainwright 分析师 A. Maldonado 现在预计该公司本季度每股收益为（$0.32），高于之前预测的（$0.36）。HC Wainwright 对该股票给予 “买入” 评级，目标价为$23.00。Protara Therapeutics 当前全年的共识收益预期为每股（$3.32）。HC Wainwright 还发布了 Protara Therapeutics 2026 年第一季度每股收益预期为（$0.33），2026 财年每股收益预期为（$1.37），2027 财年每股收益预期为（$1.70），2028 财年每股收益预期为（$0.95）以及 2029 财年每股收益预期为（$0.34）。</p>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Protara Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Protara Therapeutics has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $19.60.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的报告中重新发布了 Protara Therapeutics 的 “卖出（d-）” 评级。一位分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，还有一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Protara Therapeutics 的平均评级为 “适度买入”，共识目标价为$19.60。</p>
</div><p>Get <strong>Protara Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Protara Therapeutics</strong> 警报：</p>
</div><p><strong>Get Our Latest Analysis on TARA</strong></p>
<div class="lb-trans"><p><strong>获取我们对 TARA 的最新分析</strong></p>
</div><h2>Protara Therapeutics Trading Up 2.6%</h2>
<div class="lb-trans"><h2>Protara Therapeutics 股价上涨 2.6%</h2>
</div><p>TARA stock opened at $7.56 on Wednesday. The company's 50 day moving average is $5.07 and its 200 day moving average is $3.82. The stock has a market cap of $291.72 million, a price-to-earnings ratio of -4.67 and a beta of 1.59. Protara Therapeutics has a 1-year low of $2.48 and a 1-year high of $10.48.</p>
<div class="lb-trans"><p>TARA 股票在星期三开盘价为$7.56。该公司的 50 日移动平均线为$5.07，200 日移动平均线为$3.82。该股票的市值为$2.9172 亿，市盈率为-4.67，贝塔值为 1.59。Protara Therapeutics 的 1 年最低价为$2.48，1 年最高价为$10.48。</p>
</div><p>Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.08.</p>
<div class="lb-trans"><p>Protara Therapeutics（纳斯达克代码：TARA - 获取免费报告）最近一次发布财报是在 11 月 10 日星期一。该公司报告本季度每股收益为（$0.31），超出共识预期的（$0.39）$0.08。</p>
</div><h2>Institutional Trading of Protara Therapeutics</h2>
<div class="lb-trans"><h2>Protara Therapeutics 的机构交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new stake in Protara Therapeutics during the 2nd quarter valued at $47,000. Velan Capital Investment Management LP increased its position in shares of Protara Therapeutics by 5.6% in the first quarter. Velan Capital Investment Management LP now owns 1,667,800 shares of the company's stock valued at $7,105,000 after acquiring an additional 88,800 shares during the period. Walleye Capital LLC raised its stake in shares of Protara Therapeutics by 3.9% during the first quarter. Walleye Capital LLC now owns 229,454 shares of the company's stock valued at $977,000 after acquiring an additional 8,640 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Protara Therapeutics during the first quarter worth about $64,000. Finally, American Century Companies Inc. bought a new stake in shares of Protara Therapeutics in the first quarter worth about $154,000. Hedge funds and other institutional investors own 38.13% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近对该股票的持仓进行了调整。洛杉矶资本管理公司在第二季度购买了 Protara Therapeutics 的新股份，价值$47,000。Velan Capital Investment Management LP 在第一季度增加了对 Protara Therapeutics 的持仓，增幅为 5.6%。Velan Capital Investment Management LP 现在拥有 1,667,800 股该公司的股票，价值$7,105,000，在此期间又收购了 88,800 股。Walleye Capital LLC 在第一季度将其在 Protara Therapeutics 的股份提高了 3.9%。Walleye Capital LLC 现在拥有 229,454 股该公司的股票，价值$977,000，在上个季度又收购了 8,640 股。查尔斯·施瓦布投资管理公司在第一季度购买了 Protara Therapeutics 的新股份，价值约$64,000。最后，美国世纪公司在第一季度购买了 Protara Therapeutics 的新股份，价值约$154,000。对冲基金和其他机构投资者持有该公司 38.13% 的股份。</p>
</div><h2>About Protara Therapeutics</h2>
<div class="lb-trans"><h2>关于 Protara Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.</p>
<div class="lb-trans"><p>Protara Therapeutics, Inc.是一家临床阶段的生物制药公司，致力于推进用于治疗癌症和罕见疾病的变革性疗法。该公司的主导项目是 TARA-002，一种正在进行的细胞疗法，目前处于针对非肌肉侵袭性膀胱癌和淋巴畸形的二期临床试验中。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Protara Therapeutics</li>
<li>What Are Earnings Reports?</li>
<li>History Says These are 3 Stocks to Buy for December</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Warner Bros. Sale Rumors Heat Up: What Investors Need to Know</li>
<li>3 Small Caps With Big Return Potential</li>
<li>From Science Project to Solvent: WeRide’s 761% Revenue Surge</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Protara Therapeutics 更好</li>
<li>什么是财报？</li>
<li>历史表明这三只股票适合在 12 月购买</li>
<li>高分红 REIT：它们是理想的多元化方式吗？</li>
<li>华纳兄弟出售传闻升温：投资者需要知道什么</li>
<li>三只小盘股具有巨大的回报潜力</li>
<li>从科学项目到溶剂：WeRide 的 761% 收入激增</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=TARA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Protara Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Protara Therapeutics 吗？</h2>
</div><p>Before you consider Protara Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Protara Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Protara Therapeutics 并不在名单上。</p>
</div><p>While Protara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Protara Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 对 TARA 第四季度的盈利持积极态度